Recipharm Appoints New Key Account Director for Europe
News Jan 21, 2016
Recipharm has announced the appointment of Anke Mollowitz to the role as Key Account Director. Anke has joined the Business Management team and is responsible for coordinating customer management and commercial aspects, as well as developing relationships with a selected number of customers in Europe.
This new role expands Recipharm’s sales organization and is a further step to proactively build client networks and develop a deep understanding of the customers’ business as well as initiate new business opportunities for the Recipharm Group.
After Anke’s professional education as translator and interpreter, she worked for more than 13 years in sales in a company manufacturing machines for the timber processing industry. In 2005 she joined Haupt Pharma Wülfing GmbH, member of the Aenova group since 2014. After working as sales representative and project manager, she took the position as Head of Customer Service in 2013.
Among other tasks she was responsible for acquisitions and business development within the Haupt Group. In March 2015 she became part of the Aenova sales team in addition to her responsibility as Head of Customer Service. In this position she was first contact for specific key accounts and accounts in order to enlarge existing business and generate new business for all sites of the Aenova Group.
Commenting on the appointment, Kenth Berg VP Business Management said: “I am very pleased that Anke has joined the Business Management team. With extensive knowledge and experience in the CDMO business, her contribution will be very valuable in the development of our customer relationships.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018